<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ARIPIPRAZOLE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ARIPIPRAZOLE</h1>

        <p><a href="../drugClass/PHP34569.html">ANTIPSYCHOTIC DRUGS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Maintenance in schizophrenia in patients stabilised with oral aripiprazole</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg every 1 month, to be injected into the gluteal muscle, minimum of 26 days between injections, for dose adjustment due to side effects or concomitant use of interacting drugs, consult product literature and (by mouth) 10&#8211;20 mg daily continued for 14 consecutive days after the first injection, for missed depot doses consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Schizophrenia</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10&#8211;15 mg once daily; usual dose 15 mg once daily (max. per dose 30 mg once daily), for dose adjustments due to concomitant use of interacting drugs&#8212;consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment and recurrence prevention of mania</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                15 mg once daily, increased if necessary up to 30 mg once daily, for dose adjustments due to concomitant use of interacting drugs&#8212;consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Control of agitation and disturbed behaviour in schizophrenia</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5.25&#8211;15 mg for 1 dose, alternatively usual dose 9.75 mg for 1 dose, followed by 5.25&#8211;15 mg after 2 hours if required, maximum 3 injections daily; maximum daily combined oral and parenteral dose 30 mg, for dose adjustments due to concomitant use of interacting drugs&#8212;consult product literature.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>
            <b>Aripiprazole</b> is a dopamine D<sub>2</sub> partial agonist with weak 5-HT<sub>1a</sub> partial agonism and 5-HT<sub>2A</sub> receptor antagonism.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Use only if potential benefit outweighs risk.</p><p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution in severe impairment (oral treatment preferred to intramuscular administration).</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>CNS depression</li>
            <li>comatose state</li>
            <li>phaeochromocytoma</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Anxiety, hypersalivation, malaise,
              </p>
              <p>
                <strong>uncommon:</strong> Depression, dry mouth,
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, anorexia, bradycardia, hepatitis, hyponatraemia, infection, laryngospasm, myalgia, oedema, oropharyngeal spasm, pancreatitis, pathological gambling, respiratory disorders, rhabdomyolysis, suicidal ideation, sweating, urinary disorders,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> erythema, nodules, pain at injection site, swelling,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use</h3>
              <p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose of the <i>depot injection</i>, therefore it may be a month or longer before side-effects subside.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Orodispersible tablets should be placed on the tongue and allowed to dissolve, or be dispersed in water and swallowed.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use</h3>
              <p>Correct injection technique (including the use of z-track technique) and rotation of injection sites are essential.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Patients or carers should be given advice on how to administer aripiprazole orodispersible tablets.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use</h3>
              <p>When prescribing, dispensing, or administering, check that the correct preparation is used&#8212;the preparation usually used in hospital for the rapid control of an <i>acute episode</i> (solution for injection containing aripiprazole 7.5&#8239;mg/mL) should <b>not</b> be confused with depot preparations (aripiprazole 400-mg vial with solvent), which are usually used in the community or clinics for <i>maintenance treatment</i>.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cerebrovascular disease
          </li>
          <li>
            elderly (reduce initial dose)
          </li>
        </ul>
        <ul>
          <li>
              <strong>With intramuscular use:</strong>
            when transferring from oral to depot therapy, the dose by mouth should be reduced gradually
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use</h3>
              <p>Treatment requires careful monitoring for optimum effect.</p>
            </section>
            <section class="patientParameters">
              <p>Aripiprazole does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ARIPIPRAZOLE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP74653"><a href="../medicinalForm/PHP74653.html" data-target="#PHP74653" data-action="load">Tablet</a></div>
            <div id="PHP74659"><a href="../medicinalForm/PHP74659.html" data-target="#PHP74659" data-action="load">Orodispersible tablet</a></div>
            <div id="PHP74665"><a href="../medicinalForm/PHP74665.html" data-target="#PHP74665" data-action="load">Oral solution</a></div>
            <div id="PHP74672"><a href="../medicinalForm/PHP74672.html" data-target="#PHP74672" data-action="load">Solution for injection</a></div>
            <div id="PHP74679"><a href="../medicinalForm/PHP74679.html" data-target="#PHP74679" data-action="load">Powder and solvent for suspension for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
